文献速递妇科

Ofranergene obadenovec(VB-111)联合紫杉醇治疗铂耐药卵巢癌的I/II期研究

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
PubMed 文献 · Gynecol Oncol · 2020-04-05

该前瞻性开放标签剂量递增I/II期研究评估VB-111联合每周紫杉醇治疗铂耐药卵巢癌。21例患者入组,17例接受治疗剂量,未观察到剂量限制性毒性。治疗剂量组CA-125 GCIG缓解率为58%,中位总生存期16.6个月,显著优于亚治疗剂量组的5.8个月(p=0.028),且疗效与免疫治疗效应相关。

要点

  • VB-111联合紫杉醇在铂耐药卵巢癌中安全耐受,未出现剂量限制性毒性。
  • 治疗剂量组CA-125缓解率达58%,中位OS为16.6个月,优于亚治疗剂量组的5.8个月。
  • 治疗后肿瘤标本显示CD8 T细胞浸润凋亡癌细胞区域,提示免疫治疗效应。

核心结论

  • VB-111联合紫杉醇治疗铂耐药卵巢癌安全耐受,良好肿瘤缓解和总生存获益与免疫治疗效应诱导相关。

研究设计与样本

  • 前瞻性、开放标签、剂量递增I/II期研究(NCT01711970),评估VB-111联合每周紫杉醇。
  • 共入组21例复发性铂耐药卵巢癌患者,17例接受治疗剂量,中位既往治疗线数为3。

主要发现

  • 未观察到剂量限制性毒性,VB-111耐受良好,仅伴轻度流感样症状。
  • 治疗剂量组可评估患者CA-125 GCIG缓解率为58%。
  • 治疗剂量组中位OS为16.6个月,亚治疗剂量组为5.8个月(p=0.028)。
  • 治疗后肿瘤标本显示细胞毒性CD8 T细胞浸润凋亡癌细胞区域。

关键数值与推荐

  • 治疗剂量组CA-125 GCIG缓解率为58%。
  • 治疗剂量组中位OS为16.6个月,亚治疗剂量组为5.8个月(p=0.028)。

临床怎么用

  • VB-111联合紫杉醇可作为铂耐药卵巢癌的潜在治疗选择,需进一步验证。
  • 治疗过程中需监测流感样症状,并关注免疫治疗相关效应。

局限性

  • 样本量小(21例),为早期剂量递增研究,结果需大样本随机试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Report final results of a phase I/II study of VB-111, a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response, in combination with paclitaxel in patients with platinum-resistant ovarian cancer. METHODS: Study NCT01711970 was a prospective, open label, dose escalation study assessing combination treatment of VB-111 and weekly paclitaxel. In the Phase I part of the study, patients were treated with escalating doses of intravenous VB-111 and paclitaxel. In Phase 2, patients were treated with therapeutic doses of VB-111 and paclitaxel 80 mg/m2. Assessments included safety, overall survival (OS), progression free survival (PFS), and tumor response (CA-125 and RECIST). RESULTS: 21 patients with recurrent platinum-resistant ovarian cancer were enrolled. 17/21 received the therapeutic dose. Patients had a median of 3 prior lines of therapy. Half of the subjects were platinum refractory, and half were previously treated with antiangiogenics. No DLTs were observed. VB-111 was well tolerated and associated with mild flu-like symptoms. In the therapeutic dose cohort, a 58% CA-125 GCIG response rate was seen in evaluable patients. The median OS was 16.6 months in patients treated with therapeutic dose compared to 5.8 months in sub-therapeutic dose (p = 0.028). Tumor specimens taken after treatment demonstrated tumor infiltrated with cytotoxic CD8 T-cells in regions of apoptotic cancer cells. CONCLUSIONS: Treatment with VB-111 in combination with paclitaxel was safe and well tolerated. Favorable tumor responses and overall survival outcomes were associated with induction of an immunotherapeutic effect.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Arend RC, Beer HM, Cohen YC, et al. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020. PMID: 32265057. doi:10.1016/j.ygyno.2020.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。